Recombinant Vaccines Market Industry Forecast till 2025
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/455
According to World Health Organization (WHO), around 18 million fatalities were caused due to inaccessibility of treatment for their illness. According to World Health Organization Report 2017, in the U.S. it is possible to prevent 2 million - 3 million deaths every year by immunization and 1.5 million deaths are easily avoided by immunization. There were around 19.5 million infants did not get basic vaccine. There is constant development in technology which lead to the manufacture of more effective vaccines for disease and companies are working for the development of new vaccines for various disease such as zika virus, cancer and others.
The global recombinant vaccine market was valued at US$ 830.2 million in 2016 and is expected to witness a robust CAGR of 6.0% during the forecast period (2017 – 2025).
Increase in the incidence of zoonotic diseases and emerging technologies expected to support the growth of recombinant vaccines market
There is a constant increase in diseases caused by bacteria or virus such as swine flu, malaria, HPV and other diseases, which has raised the demand of vaccination and lead to the eradication of diseases such as polio, and tetanus in few countries. Whit the development in technology there is development in vaccines, which are more effective than conventional vaccines and does not lead to any side effect. These vaccines are easy to administer in the body orally, intramuscular or intradermal. In the U.S. there were around 212 million malaria cases and 429,000 deaths from malaria is reported in 2015. According to Centers for Disease Control and Prevention report 2017, in the U.S. there were around 49.9% of the children between the ages of 6 months to 17 years received an influenza vaccine.
Continuous investment in research & development for the development of new vaccines and increased awareness and pet adoption are expected to fuel the growth of recombinant vaccines
There are various companies working on the development of vaccine for various disease, which have affected human beings in short span of time such as Ebola, Zika, and H1N1 flu. The companies also working for the development of cancer vaccines different type of cancer includes lung cancer, blood cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, prostate cancer, solid tumors cancer , breast cancer are the target area for recombinant vaccine development, which may expected to support the growth of recombinant vaccine market in the near future. In 2012, according to the World Cancer Research Fund International, globally around 1.7 million new cases of breast cancer are diagnosed. Breast cancers are being targeted in active NCI supported cancer prevention or treatment clinical trials using vaccines. The vaccine therapy with or without trastuzumab in treating patients with stage IV breast cancer is in phases II clinical trial. The folate receptor alpha peptide vaccine with GM-CSF in patient with triple negative breast cancer trial phase II.
Ask for customization @ https://www.coherentmarketinsights.com/insight/request-customization/455
According to National Cancer Institute, in the U.S. there were around 1,685,210 new cases of cancer was reported and 595,690 people died from cancer in 2016. According to American Society for the Prevention of Cruelty to Animals, in the U.S. there were around 3.2 million shelter animals are adopted each year (1.6 million dogs and 1.6 million cats) and adoption of pets are expected to increase, which in turn raise the demand for recombinant vaccines for animals in near future.
Some major key players in the recombinant vaccines market include Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi S A, Pfizer Inc., and Bharat Biotech.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recombinant Vaccines Market Industry Forecast till 2025 here
News-ID: 1182750 • Views: 224
More Releases from Coherent Market Insights
Continuous Glucose Monitoring Market Generated Opportunities by Top Manufacturer …
The Continuous Glucose Monitoring (CGM) Devices Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Continuous Glucose Monitoring (CGM) Devices Market report presents a lucid picture of the current industry landscape, including the
Impact of COVID-19 Pandemic on Remote Patient Monitoring Devices Market Future S …
The Remote Patient Monitoring Devices Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Remote Patient Monitoring Devices Market report presents a lucid picture of the current industry landscape, including the historical and
ENT Chairs Market To Register Phenomenal Growth By Top Manufactures: Atmos Medic …
The ENT Chairs Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The ENT Chairs Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based
Impact of COVID-19 Pandemic on Stairlifts Market Future Scope Competitive Analys …
The Stairlifts Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Stairlifts Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based on value,
More Releases for Recombinant
Human Recombinant Insulin Market Growth Analysis
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry
Global Recombinant Factor VIII Market Research Report
This report studies the global Recombinant Factor VIII market status and forecast, categorizes the global Recombinant Factor VIII market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Shire (Baxter) Bayer CSL Pfizer Biogen Octapharma NovoNordisk Geographically, this report studies the top producers
United States Recombinant Vaccine Market Report
In this report, the United States Recombinant Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share
Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Global Human Recombinant Insulin Market – Industry Insights
Discovery of insulin is considered to be one of the most important events in the history of the diabetes treatment. Furthermore, major advances in human insulin technology is the synthesis of human insulin analogue by recombinant technology. Currently, human insulin delivery system available for the administration of insulin include insulin syringes, insulin pumps, jet injections, and pens. Key players are focused on developing recombinant human insulin instead of animal-based insulin,
Global Human Recombinant Insulin Market – Industry Insights
Various government and private research organizations are engaged research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, American Diabetes Association (ADA) invested US$ 807.4 million in more than 4,700 research projects in diabetes research since 1952